Press Release
American Oncology Network, LLC, a high-growth medical oncology provider with a focus on supporting the long-term viability of cancer treatment in community-based settings, recently announced the appointment of Karen Pilley, as the organization’s Chief Revenue Cycle Officer.
Vivek Subbiah, MD, discusses the significance of the approval of dabrafenib plus trametinib for adult and pediatric patients 6 years or older with unresectable or metastatic BRAF V600E–mutant solid tumors and highlights future directions for tumor agnostic drug development.
Maurie Markman, MD, discusses maintenance therapy and how it differs from other strategies in cancer care.
The dual immunotherapy combination comprised of nivolumab given at 1 mg/kg and ipilimumab given at 3 mg/kg provided durable responses and long-term survival benefit in patients with advanced hepatocellular carcinoma following treatment with sorafenib.
Jacob Berchuck, MD, discusses the effect of the approval of darolutamide tablets on the standard of care for patients with metastatic hormone sensitive prostate cancer.
Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Pembrolizumab monotherapy continued to demonstrate durable antitumor activity with promising overall survival in patients with advanced hepatocellular carcinoma who received prior treatment with sorafenib, according to updated data from cohort 1 of the phase 2 KEYNOTE-224 trial.
Treatment with frontline panitumumab and mFOLFOX6 led to a significant improvement in overall survival, plus higher response rates and R0 resection rates, compared with bevacizumab and mFOLFOX6 in patients with RAS wild-type metastatic colorectal cancer.
Joshua K. Sabari, MD, discusses the significance of adagrasib as an agent with favorable central nervous system penetration and importance of performing next-generation sequencing in all patients with non–small cell lung cancer to detect KRAS G12C mutations.
After HER2 was established as an actionable target in gastric cancer, its amplification has become a key biomarker of interest for other gastrointestinal cancers.
Press Release
Joan Hogan, DSW, LCSW, OSW-C, and Rosemarie Slirzewski, MSW, LCSW, expand on the unique needs and challenges of LGBTQ+ individuals who are faced with cancer.
Anne M. Noonan, MBBCh, discusses prominent new therapies in hepatocellular carcinoma, the benefits of immunotherapy in gastric cancer, chemotherapy developments in pancreatic cancer, and the importance of considering HER2-targeted therapy in metastatic colorectal cancer.
The FDA has granted an accelerated approval to fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic non–small cell lung cancer whose tumors have activating HER2 mutations, as detected by an FDA-approved test, and who have received previous systemic therapy.
Single-agent tolinapant generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, according to data from the phase 2 ASTX660-01 trial.
The FDA has granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test.
Andrew H. Ko, MD, discusses the multitude of treatment options for patients with gastroesophageal cancer, emerging combinations in hepatocellular carcinoma, and how HER2 expression can drive therapy decisions in colorectal cancer.
The FDA has expanded its approval of the VENTANA MMR RxDx panel to identify patients with mismatch repair–deficient solid tumors and as a companion diagnostic assay to determine eligibility for pembrolizumab as a treatment for patients with mismatch repair–proficient endometrial cancer.
The FDA has granted priority review to a new drug application seeking the approval of elacestrant for use in patients with estrogen receptor–positive/HER2-negative advanced or metastatic breast cancer.
Press Release
The National Cancer Institute-designated Montefiore Einstein Cancer Center has partnered with the Price Family Foundation to fund 8 research teams developing novel cancer therapies and improving cancer outcomes for historically marginalized communities in the Bronx.
Jean-Marie Michot, MD, discusses the methods and rationale for the CC-99282-NHL-001 study.
Sacituzumab govitecan-hziy is now a category 1 preferred recommendation in triple-negative breast cancer and a category 2A preferred recommendation in HR-positive/HER2-negative disease.
The National Cancer Act of 1971 introduced the concept of a “war on cancer,” which has since affected the language we use when discussing the disease.
Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.
Press Release
Robert Wood Johnson University Hospital, a RWJBarnabas Health facility, has been recognized as one of the top five hospitals in New Jersey and a top 20 Regional Best Hospital in the New York Metropolitan area by U.S. News & World Report in the annual Best Hospitals rankings.
Idecabtagene vicleucel elicited a statistically significant improvement in progression-free survival vs standard combination regimens in patients with relapsed/refractory multiple myeloma who had received 2 to 4 lines of prior therapy.
Primary payer data reported by cancer registries are subject to measurement error and can result in biased estimates of insurance-related policy effects.
The Kidney Cancer Treatment guidelines, housed within the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, have been revised, granting tivozanib Category 1 status as a subsequent therapy for patients with renal cell carcinoma who have received at least 2 prior lines of treatment.
Treatment with durvalumab and concurrent radiotherapy provided a significant benefit in progression-free survival in patients with locally advanced non–small cell lung cancer, meeting the primary end point of the phase 2 DOLPHIN trial.
Although frontline treatment with avelumab resulted in a longer overall survival and progression-free survival than that observed with platinum-based chemotherapy in patients with advanced non–small cell lung cancer and high PD-L1 positivity, this difference did not achieve statistical significance.
Sunvozertinib monotherapy produced meaningful responses in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior treatment with platinum-based chemotherapy, according to pooled data from the phase 1 WU-KONG1 and WU-KONG2 trials, plus the phase 2 WU-KONG6 trial.
